Citations

Clear

3053 citation(s) found for "Patel, A".

Codon bias variation in Staphylococcus aureus
O’Connor, Kathleen , Mallinger, Benjamin D, Bedard, Nicholas A. , Patel, Robin , Patel, Robin , Bedard, Nicholas A

Mayo Clinic

PLOS One | September 9, 2026 | Volume: 21 | Issue: 9 | Pages: e0356997

10.1371/journal.pone.0356997 | PMID 42715188 Get It

Background Staphylococcus aureus causes a multiplicity of human diseases acquired in community and healthcare settings alike around the globe. While most studies focus on coding changes to assess genome evolution and study genetic adaptation, interrogation of silent mutations in the form of synonymous codon usage bias is less well-studied. As such, understanding of patterns in codon bias at the gene and genome levels, and how codon bias impacts protein expression in S. aureus remains incomplete. Methods The codon bias of 2,565 protein encoding genes from NCTC 8325 was queried against all publicly available closed S. aureus genomes. Using public BioSample data, genomes were sorted by disease state, submitting institution, and collection site. Codon bias was assessed at the level of gene and genome using the codon adaptation index (CAI), calculated using 30S and 50S ribosomal genes. Gene set enrichment analysis was applied to determine associations between physiological functions, CAI gene scores, and interquartile ranges. CAI scores were also compared to an in vitro S. aureus proteomics database to correlate codon bias and protein expression. Results CAI scores varied within and between isolates at the gene and genome levels. Genes with ribosome-associated functions were most enriched among high CAI genes, and had low CAI interquartile ranges (IQR), suggesting selective pressure to maintain high expression of these genes across all S. aureus isolates. Genome sequences submitted by Aga Khan University Hospital, Nairobi, Kenya were most different from others. For the LAC USA 300 strain, CAI and protein expression were moderately positively correlated (cor = 0.534, p < 2.2e-16). Conclusions Codon bias in S. aureus was shown to vary between gene, and to be a source of genetic variation between isolates; CAI and in vitro protein expression were positively correlated.
Locally Invasive Conjunctival Squamous Cell Carcinoma Refractory to Plaque Radiotherapy
Dalvin, Lauren A., Trejo‐Lopez, Jorge , Smith, Wendy M. , Patel, Sanjay V , Dalvin, Lauren A. , Wagner, Lilly H. , Patel, Sanjay V.

Mayo Clinic

Cornea | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ico.0000000000004259 | PMID 42634946 Get It

Purpose: To describe a case of locally invasive conjunctival squamous cell carcinoma (SCC) refractory to plaque radiotherapy. Case Description: A 69-year-old man presented with a recurrent conjunctival tumor after 6 previous cycles of topical 5-fluorouracil chemotherapy and excisional biopsy showing invasive SCC with positive margins. There was a mild anterior chamber reaction. By the time of repeat excisional biopsy, the conjunctiva had ulcerated with underlying scleralysis associated with histopathologic evidence of scleral involvement by SCC. After subsequent tectonic scleral patch grafting, plaque radiotherapy was applied after which the disease appeared to be controlled for 9 months. The eye then developed progressive conjunctival ulceration and scleralysis with progressive ectropion. Exenteration was performed, revealing locally invasive SCC into palpebral conjunctiva, ciliary body, and choroid. Conclusions: Conjunctival SCC can be locally invasive with destruction of the globe, despite plaque radiotherapy. Clinicians should be suspicious of invasive diseases in cases of ocular surface squamous neoplasia that are poorly responsive to topical chemotherapy. Associated anterior chamber cell and progressive scleralysis should also raise concern for invasive malignancy.
Performance of general-population breast cancer risk prediction models in an international consortium
Brantley, Kristen D. , Ahearn, Thomas U, Norton, Emily , MacInnis, Robert, Palmer, Julie R, Vachon, Celine M, Beane-Freeman, Laura, Frost, Reuben, Zirpoli, Gary, Neuhouser, Marian L, Barnett, Matthew, Teras, Lauren R, Patel, Alpa V, Bodelon, Clara, Spielfogel, Emma S. , Kirsh, Victoria A. , Langseth, Hilde , Milne, Roger L, Haiman, Christopher, Scott, Christopher G, Eliassen, A. Heather, Rosner, Bernard, Willett, Walter C, Chen, Yu, Wu, Fen , Zheng, Wei, Long, Jirong, O'Brien, Katie M, Sandler, Dale P, Linet, Martha S. , Anderson, Garnet, Larson, Joseph C. , Lee, I-Min, Chatterjee, Nilanjan, Kraft, Peter, Brantley, Kristen D , Kirsh, Victoria A , Ahearn, Thomas U. , Norton, Emily L., Palmer, Julie R. , Fortner, Renée T. , Vachon, Celine M. , González, Amy Berrington de , Bertrand, Kimberly A. , Zirpoli, Gary , Barnett, Matthew J , Teras, Lauren R. , Hodge, James M. , Patel, Alpa V , Bodelón, Clara , Lacey, James V. , Rohan, Thomas E. , Tsuruda, Kaitlyn M. , Milne, Roger L , Rosner, Bernard, Willett, Walter C. , Romanos-Nanclares, Andrea , Zheng, Wei , Long, Jirong, O’Brien, Katie M. , Sandler, Dale P. , Kitahara, Cari M. , Anderson, Garnet L. , Lee, I-Min, García‐Closas, Montserrat , Chatterjee, Nilanjan

Mayo Clinic

No container title available | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.20.26360899 Get It

Background: Several breast cancer (BC) risk prediction models have been developed to provide personal risk assessments. Though individually validated, their performance has not been systematically evaluated across a wide range of populations or ages. Methods: We harmonized individual-level baseline questionnaire data and incident BC diagnoses from 21 cohorts from North America, Europe, and Australia participating in the Breast Cancer Risk Prediction Project. Five-year absolute risk of invasive BC was estimated for five established risk prediction models using classical risk factors only. Discrimination was evaluated by area under the curve (AUC). Calibration was assessed using average and risk-decile specific expected to observed (E/O) ratios. Performance metrics were meta-analyzed across cohorts and models. Metaregression tested associations between cohort characteristics and performance metrics. Results: This analysis included 1,595,977 women aged 20-75 years, enrolled in studies between 1976-2015, with 19,062 (1.2%) invasive BC cases ascertained within 5 years from exposure assessment. Age-adjusted AUCs were similar across models and cohorts (pooled AUCs by model: 0.57-0.58), while E/O ratios varied substantially (pooled E/O ratios by model: 0.83-1.25). Overestimation was common among predicted high-risk individuals (>3%). No appreciable differences in model performance by cohort age, birth year, race, and variable missingness emerged. Calibration improved after assigning race-specific incidence rates. Conclusion: Existing BC risk prediction models provided similar risk discrimination across multiple cohorts, although there was overestimation of risk for high-risk individuals. Performance variation across cohorts was not driven by specific characteristics, which supports development of a unified risk model for diverse populations that leverages appropriate incidence rates.
Engineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma Cells
Gondaliya, Piyush , Zinn, Dylan A. , Sayyed, Adil Ali , Driscoll, Julia, Mensali, Nadia , Yan, Irene K. , Patel, Tushar , Ali Sayyed, Adil , Driscoll, Julia , Wälchli, Sébastien , Patel, Tushar

Mayo Clinic

Molecular Pharmaceutics | August 17, 2026 | Volume: 23 | Issue: 9 | Pages: 4540-4552

10.1021/acs.molpharmaceut.6c00219 | PMID 42704135 Get It

Abstract The use of natural killer (NK) cells for the treatment of solid tumors such as cholangiocarcinoma has been hindered by challenges related to cell production, persistence and trafficking, as well as by reduced efficacy within an immunosuppressive tumor microenvironment. Antitumor immunity can be reduced by the interaction of NK cell expressed programmed cell death protein 1 (PD1) with ligands on tumor and other cells within the tumor microenvironment. The antitumor effect of NK cells is enhanced in cells engineered to express a truncated PD1 without an intracellular domain. The cytolytic potential and therapeutic efficacy of extracellular vesicles (EVs) derived from human NK cells expressing truncated PD1 was evaluated as a cell-free therapeutic to overcome some limitations faced by cell therapies. We demonstrate the feasibility of efficient expansion, production and isolation of therapeutic vesicles from human NK cell lines and from engineered NK92 cells expressing truncated PD1. The cytotoxic efficacy of these therapeutic vesicles was validated in both monolayer tumor cell cultures and in multicellular tumor spheroids. Concomitant administration of gemcitabine upregulated NKG2D ligands on tumor cells and increased susceptibility to NK cell and to NK cell derived EV mediated killing. These findings position engineered NK cell derived-EVs as a scalable and promising cell-free immunotherapeutic for cholangiocarcinoma.
NCCN Guidelines® Insights: Survivorship, Version 3.2026
Peterson, L., McDonough, Allison L. , Ansbaugh, Shannon M., Heredia, Ella J. Ariza, Armenian, Saro, Baker, K. Scott, Cathcart-Rake, Elizabeth J., Cohen, Stuart H. , Fairman, Nathan, Feliciano, Josephine, Flores, Tessa , Gabel, Nicolette , Hill‐Kayser, Christine E. , Hock, Karen, Kline-Quiroz, Cristina, Lee, Nita K., Mooney, Kathi, Moryl, Natalie , Neuman, Heather, Overholser, Linda, Patel, Chirayu G. , Porpiglia, Andrea, Saidain, Ava, Schapira, Lidia , Smith, Sophia K., Tenner, Laura, Ah, Diane Von , Zee, Phyllis, Freedman-Cass, Deborah, McMillian, Nicole, Ariza‐Heredia, Ella , Armenian, Saro H. , Ballinger, Tarah Jean , Cathcart-Rake, Elizabeth , Day, Andrew T. , Evgeniou, Evgenios , Feliciano, Josephine , Friedman, Debra L. , Hock, Karen , Kline‐Quiroz, Cristina , Moore, Halle C. F. , Neuman, Heather B. , Overholser, Linda , Porpiglia, Andrea S., Rogers, Laura Q. , Yang, Eric H. , Freedman-Cass, Deborah A., McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0039 | PMID 42607712 Get It

The NCCN Guidelines for Survivorship offer guidance for health care providers who care for survivors of adult-onset cancer. These guidelines include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from cancer and its treatment and provide a framework for care coordination. They also present guidance for helping cancer survivors to enhance their wellness and maintain a healthy lifestyle. This article summarizes the panel’s current recommendations and recent updates regarding anxiety, depression, distress, and trauma in cancer survivors.
Multicenter clinical evaluation of a fully automated multiplex HSV-1, HSV-2, and VZV real-time PCR assay
Yao, Joseph, McElvania, Erin , Al-Ghoul, Mohammad, Patel, Parul, Kular, Rupinder , Wuitschick, Jeffrey, Huang, Shihai , Birdsall, John, Pestova, Ekaterina, Dhiman, Neelam, McElvania, Erin , Patel, Parul, Kular, Rupinder K. , Wuitschick, Jeffrey D., Birdsall, John, Pestova, Ekaterina V. , Dhiman, Neelam

Mayo Clinic

Journal of Clinical Microbiology | August 14, 2026 | Volume: 64 | Issue: 9 | Pages: No page available

10.1128/jcm.00535-26 | PMID 42599190 Get It

ABSTRACT Herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella-zoster virus (VZV) are associated with a range of clinical manifestations depending on the anatomical site of infection. HSV and VZV lesions often exhibit similar phenotypical characteristics, making clinical differentiation challenging. Detection and differentiation of HSV-1, HSV-2, and VZV are essential for diagnosis and treatment management. An automated multiplex real-time PCR assay, Alinity m HSV 1 & 2/VZV assay, was developed to detect and differentiate HSV-1, HSV-2, and VZV. The assay was validated for use with cutaneous and mucocutaneous lesion swab specimens collected in commercial viral transport media from symptomatic patients. The assay demonstrated a limit of detection of 5.90 TCID 50 /mL for HSV-1, 2.07 TCID 50 /mL for HSV-2, and 0.055 TCID 50 /mL for VZV. Testing with clinical swab specimens demonstrated greater than 95% clinical sensitivity and specificity for all three analytes. The Alinity m HSV 1 & 2/VZV assay provides a reliable and accurate method for detection and differentiation of HSV-1, HSV-2, and VZV in lesion swab specimens for improved diagnostic accuracy and patient management. IMPORTANCE Herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella-zoster virus (VZV) can cause skin and mucocutaneous lesions that often appear clinically similar, making accurate diagnosis difficult without laboratory testing. Rapid and reliable identification of the causative virus is important because patient counseling, treatment decisions, and infection management differ among these infections. In this multicenter study, a fully automated molecular assay was evaluated that simultaneously detects and differentiates HSV-1, HSV-2, and VZV from a single-lesion swab specimen. Testing of more than 1,200 clinical specimens demonstrated high sensitivity and specificity for all three viruses. The assay also offers a streamlined workflow with minimal hands-on time and rapid turnaround. These findings support the use of this multiplex assay as a practical diagnostic tool that can improve laboratory efficiency and provide clinicians with timely, accurate results to guide patient care.
Augmented Reality and Three-Dimensional Printing as an Aid to Surgical Planning in Modern Microtia Reconstruction: Response to Authors
Gomez, Diego A., Hashemi, Kiana, Sharma, Ishpriya , Demeris, Alexander, Patel, Pushpak , Kellogg, Brian C. , Dusseldorp, Joseph R., Barone, Angelo A. Leto, Aycart, Mario A. , Dusseldorp, Joseph R. , Barone, Angelo A. Leto

Mayo Clinic

Journal of Craniofacial Surgery | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/scs.0000000000013278 | PMID 42598810 Get It

Global Transcriptional Differences in Staphylococcus aureus Biofilm-Associated Genes in a brpR Mutant Compared to Wild-Type Strain
Dyce, Hailey, Johnson, Stephen , Sharp, Isabelle, Schwan, William R. , Schweiger, Paul , Johnson, Stephen , Schwan, William R , Patel, Robin

Mayo Clinic

Antibiotics | August 14, 2026 | Volume: 15 | Issue: 8 | Pages: 787

10.3390/antibiotics15080787 | PMID 42650712 Get It

Background: Staphylococcus aureus causes bloodstream and skin infections in humans. The prevalence of multidrug-resistant S. aureus strains means new antibiotics are needed. A novel antimicrobial drug named SK-03-92, a synthetic aromatic organic stilbenoid compound, kills S. aureus cells within 30 min, but an increase in both biofilm formation and persister cells occurs. SK-03-92 treatment downregulates transcription of the biofilm regulating protein regulator (brpR) gene and biofilm regulating protein sensor (brpS) gene in S. aureus. BrpR/BrpS system may be a LytTR regulatory system tied to biofilm formation, creation of persister cells, and late-stage competence in S. aureus. The aim of this study was to determine what biofilm, late-stage competence, and persister-associated genes were regulated in a brpR mutant compared to wild-type strains. Methods: In this study, involvement of BrpR in regulating other genes was assessed by comparing transcriptional changes in a brpR mutant strain to the S. aureus parent strain via RNA sequencing (RNA-Seq). Bioinformatic analysis was then performed on the RNA-Seq data to assess what biochemical pathways might be involved. Results: From these analyses, 440 genes were identified that had significant differences in transcript abundance when comparing the brpR mutant to wild-type strains. Quantitative reverse transcription polymerase chain reaction analysis confirmed bacA, icd, metE, and pdhA transcript levels were lower, whereas alr and mraY were higher in the brpR mutant versus wild-type strain. Furthermore, an enzymatic assay targeting NADH production from the pyruvate dehydrogenase complex showed lower levels in the mutant compared to wild-type strain. Conclusions: Overall, the study demonstrated several biosynthetic pathways tied to biofilm formation and late-stage competency may be regulated by BrpR and some potential leads for the mechanism of action of the SK-03-92 drug were uncovered.
Pharmacoexposomics: The Environmental Complement to Pharmacogenomics to Advance Precision Medicine
Reho, Paolo, Athreya, Arjun P. , Hripcsak, George, Kim, Soon-Mi, Li, Shuzhao, Walker, Douglas I., Patel, Chirag J., Miller, Gary W., Reho, Paolo , Thaker, Vidhu , Cremers, Serge , Go, Young‐Mi , Hripcsak, George , Hu, Xin , Jones, Dean P. , Lazaridis, Konstantinos N. , Li, Shuzhao, Pennell, Kurt D. , Singh, Randolph R. , Walker, Douglas Ian , Patel, Chirag J.

Mayo Clinic

Annual Review of Pharmacology and Toxicology | August 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1146/annurev-pharmtox-062624-113658 | PMID 42594291 Get It

Despite advances in pharmacogenomics that have led to innovative therapeutic strategies, substantial interindividual variability in drug efficacy and toxicity persists. Both endogenous and exogenous factors contribute to this unexplained variation, resulting in suboptimal treatment effectiveness, unnecessary healthcare costs, preventable mortality, and significant human suffering. The emerging field of exposomics is aimed at addressing the complex exposures that impact human health and offers an opportunity to interrogate how these exposures influence drug actions and outcomes. Here, we introduce pharmacoexposomics as a complementary framework that systematically quantifies the body's metabolic response to drug and environmental exposures using high-resolution mass spectrometry. We then present IndiPHARM (Individualized Pharmacology), a multi-institution, Advanced Research Projects Agency for Health–supported platform designed to integrate population-scale pharmacoexposomics with pharmacogenomics and clinical data to elucidate interindividual variability in drug response, identify adverse reactions, and inform tailored, effective treatment strategies that advance precision medicine.
In vitro evaluation of vancomycin-loaded Marlex mesh against staphylococci isolated from periprosthetic joint infection
Hellou, Mona Mustafa , Karau, Melissa J. , Perez, Sergio F. Guarin , Restrepo, Diego J. , Mandrekar, Jay, Bedard, Nicholas A. , Patel, Robin , Abdel, Matthew P. , Mustafa Hellou, Mona , Guarin Perez, Sergio F , Restrepo, Diego J. , Patel, Robin , Abdel, Matthew P , Bedard, Nicholas A , Mandrekar, Jay

Mayo Clinic

Bone & Joint Research | August 13, 2026 | Volume: 15 | Issue: 8 | Pages: 998-1004

10.1302/2046-3758.158.bjr-2025-0522.r2 | PMID 42586555 Get It

Aims Extensor mechanism disruption is a major complication following total knee arthroplasty, with treatment often consisting of extensor mechanism reconstruction utilizing monofilament polypropylene mesh (Marlex mesh, C. R. Bard, Inc). Infection following this procedure is devastating, often resulting in revision surgery and mesh removal, with permanent limb dysfunction. This study evaluated the in vitro ability of vancomycin-loaded polypropylene mesh to inhibit growth of isolates of three Staphylococcus species from patients with periprosthetic joint infection. Methods The mesh was prepared in two configurations – single-layer and eight-layer – and soaked for ten minutes in either sterile water (control) or vancomycin solution (50 mg/ml), after which the mesh was placed on tryptic soy agar plates inoculated with staphylococci and incubated at 37°C for 18 to 24 hours. Zones of inhibition were measured daily over seven days, with mesh transferred to freshly inoculated plates daily. Testing was performed in triplicate, with experiments repeated three times for each bacterial isolate. A total of 30 clinical isolates were tested (five methicillin-susceptible Staphylococcus epidermidis , five methicillin-resistant S. epidermidis , ten methicillin-resistant Staphylococcus aureus , and ten Staphylococcus lugdunensis ). Results Across all species, the eight-layer vancomycin-loaded mesh produced statistically significantly larger median zones of inhibition than the single-layer mesh. The antibacterial activity of the eight-layer mesh persisted through to day 7, while the single-layer mesh showed reduced activity by days 4 to 5. Conclusion Compared with single-layer vancomycin-loaded mesh, multilayer vancomycin-loaded mesh, which mimics clinical application, provides enhanced and sustained antibacterial activity in vitro. Cite this article: Bone Joint Res 2026;15(8):998–1004.